PMID- 31173211
OWN - NLM
STAT- MEDLINE
DCOM- 20191230
LR  - 20200225
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 20
IP  - 2
DP  - 2019 Aug
TI  - The therapeutic potential of epigallocatechin‑3‑gallate against human oral 
      squamous cell carcinoma through inhibition of cell proliferation and induction of 
      apoptosis: In vitro and in vivo murine xenograft study.
PG  - 1139-1148
LID - 10.3892/mmr.2019.10331 [doi]
AB  - Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors in 
      the oral region. Despite current therapeutic strategies, the survival rate has 
      not been improved for several decades. Thus, it is important to develop a novel 
      approach for the treatment of OSCC. Epigallocatechin‑3‑gallate (EGCG) is a major 
      constituent of green tea and has previously been demonstrated to inhibit the 
      growth of several types of cancer cells. However, few studies have investigated 
      the effect of EGCG on human OSCC cells, especially in experimental animal models. 
      The aim of the present study was to evaluate the therapeutic potential of EGCG 
      for targeting human OSCC in vitro and in vivo. In the in vitro experiments, EGCG 
      suppressed HSC‑3 cell viability in a time‑ and dose‑dependent manner. Cell cycle 
      analysis revealed that EGCG induced G1 phase arrest of the tumor cells. Apoptosis 
      was examined by Annexin V and propidium iodide staining, assays of caspase‑3 and 
      -7 activity and TdT‑mediated dUTP nick end labeling (TUNEL) staining. Treatment 
      with EGCG significantly increased caspase‑3 and -7 activities, and the percentage 
      of apoptotic cells when compared with control cells. In the in vivo xenograft 
      experiment on mice, EGCG treatment resulted in a 45.2% reduction in tumor size as 
      compared with the control group without weight loss. In vivo cell proliferation 
      and apoptosis were assessed by immunohistochemical Ki‑67 staining and the TUNEL 
      staining. There were significant differences in Ki‑67 expression between the EGCG 
      treatment group and control group, and the percentage of apoptotic cells in the 
      EGCG treatment group was significantly greater than that in the control group. 
      These results indicated that EGCG significantly inhibited cell proliferation by 
      affecting the cell cycle progression and apoptosis in vitro and in vivo. These 
      findings suggest that EGCG may have clinical applications as a novel approach to 
      oral‑cancer therapy.
FAU - Yoshimura, Hitoshi
AU  - Yoshimura H
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
FAU - Yoshida, Hisato
AU  - Yoshida H
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
FAU - Matsuda, Shinpei
AU  - Matsuda S
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
FAU - Ryoke, Takashi
AU  - Ryoke T
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
FAU - Ohta, Keiichi
AU  - Ohta K
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
FAU - Ohmori, Masahiro
AU  - Ohmori M
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
FAU - Yamamoto, Satoshi
AU  - Yamamoto S
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
FAU - Kiyoshima, Tamotsu
AU  - Kiyoshima T
AD  - Laboratory of Oral Pathology, Division of Maxillofacial Diagnostic and Surgical 
      Sciences, Faculty of Dental Science, Kyushu University Fukuoka 812‑8582, Japan.
FAU - Kobayashi, Motohiro
AU  - Kobayashi M
AD  - Department of Tumor Pathology, Unit of Pathological Sciences, Division of 
      Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui 
      910‑1193, Japan.
FAU - Sano, Kazuo
AU  - Sano K
AD  - Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, 
      Division of Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, 
      Fukui 910‑1193, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190604
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Carcinoma, Squamous Cell/*drug therapy/physiopathology
MH  - Catechin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Mouth Neoplasms/*drug therapy/physiopathology
MH  - Xenograft Model Antitumor Assays
PMC - PMC6625387
EDAT- 2019/06/08 06:00
MHDA- 2019/12/31 06:00
PMCR- 2019/06/04
CRDT- 2019/06/08 06:00
PHST- 2018/10/19 00:00 [received]
PHST- 2019/05/10 00:00 [accepted]
PHST- 2019/06/08 06:00 [pubmed]
PHST- 2019/12/31 06:00 [medline]
PHST- 2019/06/08 06:00 [entrez]
PHST- 2019/06/04 00:00 [pmc-release]
AID - mmr-20-02-1139 [pii]
AID - 10.3892/mmr.2019.10331 [doi]
PST - ppublish
SO  - Mol Med Rep. 2019 Aug;20(2):1139-1148. doi: 10.3892/mmr.2019.10331. Epub 2019 Jun 
      4.